Akers' set to double output with flotation proceeds
This article was originally published in Clinica
US POC diagnostics company Akers Biosciences says it will double its diagnostic kit manufacturing output to 36 million units annually with the proceeds from its recent UK AIM listing. The company raised £3.4 million ($4.9 million) this month, capitalising it at £54 million, with its 2.25 million share issue. Kit production will "expand across the street" at the company's New Jersey plant, where new facilities will be equipped, said CEO Ray Akers.
You may also be interested in...
The director of adult immunizations at Johns Hopkins International Vaccine Access Center talks to Scrip about undertaking a massive COVID-19 vaccination effort in the US.
P&G’s oral care business drove 35% of total category market growth in the firm’s fiscal 2020 and exemplifies its growth strategy for all segments – grow entire categories rather than take competitors’ market share, says CFO Jon Moeller.
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.